Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients;Galectin-3 als neuer Biomarker diastolischer Funktionsstörung bei Hämodialysepatienten

Herz

Volumn 40, Issue 5, 2015, Pages 788-794

  Gurel, Ozgul Malcok ^a   Yilmaz, Hakki ^b   Celik, Tugrul H ^a   Cakmak, Muzaffer ^a   Namuslu, Mehmet ^a   Bilgiç, Ayse M ^b   Bavbek, Nuket ^b   Akcay, Ali ^b   Eryonucu, Beyhan ^a  

^a TURGUT OZAL UNIVERSITY   (Turkey)

^b ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Biomarker; Diastolic dysfunction; Doppler echocardiography; Galectin 3; Hemodialysis

Indexed keywords

DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; GALECTIN 3; HEMOGLOBIN; HEMOGLOBIN A1C; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE MARKER; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; BLOOD; CONTROLLED CLINICAL TRIAL; ECHOGRAPHY; ETIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY;

BIOMARKERS; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84939265050     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-015-4303-6     Document Type: Article

References (34)

1. Collins AJ, Foley RN, Herzog C et al (2010) Excerpts from the US Renal Data System 2009 Annual Data Report. U.S. Department of Health and Human Services The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases United States Renal Data System. Am J Kidney Dis 55(Suppl 1):1–420, A6–7
2. Foley RN, Parfrey PS, Harnett JD et al (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186–192
3. Paoletti E (2012) Left ventricular hypertrophy and progression of chronic kidney disease. J Nephrol 25(6):847–850
4. Pecoits-Filho R, Barberato SH (2010) Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clin Pract 114:c242–c247
5. Kunz K, Dimitrov Y, Muller S et al (1998) Uraemic cardiomyopathy. Nephrol Dial Transplant 13(Suppl 4):39–43
6. Ahmed A, Rich MW, Sanders PW et al (2007) Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 99:393–398
7. Pecoits-Filho R, Bucharles S, Barberato SH (2012) Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment. Semin Dial 25(1):35–41
8. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194–202
9. Halley CM, Houghtaling PL, Khalil MK et al (2011) Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med 171:1082–1087
10. Kim MK, Kim B, Lee JY, Kim JS, Han BG, Choi SO, Yang JW (2013) Tissue doppler-derived E/eʼ ratio as a parameter for assessing diastolic heart failure and as a predictor of mortality in patients with chronic kidney disease. Korean J Intern Med 28(1):35–44
11. Farshid A, Pathak R, Shadbolt B, Arnolda L, Talaulikar G (2013) Diastolic function is a strong predictor of mortality in patients with chronic kidney disease. BMC Nephrol 14:280
12. Satpathy C, Mishra TK, Satpathy R, Satpathy HK, Barone E (2006) Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician 73(5):841–846
13. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160–171
14. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128
15. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B et al (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6(1):107–117
16. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–1224
17. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL (2010) Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12:826–832
18. Lok DJA, van Der Meer P, de la Porte PWB-A, Lipsic E, Wijngaarden JV, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel biomarker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323–328
19. de Boer RA, Lok DJA, Jaarsma T, van Der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68
20. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P (2012) The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 164:878–883
21. Yilmaz H, Gurel OM, Celik HT, Bozkurt A, Yildirim ME, Bilgic I, Bilgic MA, Bavbek N, Akcay A (2014) Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients. Herz doi:10.1007/s00059-014-4111-4
22. Nagueh S, Appleton C, Gillebert T, Marino P, Oh J, Smiseth O et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133
23. Krumholz HM, Larson M, Levy D (1995) Prognosis of left ventricular geometric patterns in the Framingham study. J Am Coll Cardiol 25:879–884
24. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463
25. Alnabhan N, Kerut EK, Geraci SA, McMullan MR, Fox E (2008) An approach to analysis of left ventricular diastolic function and loading conditions in the echocardiography laboratory. Echocardiography 25(1):105–116
26. Christenson RH, Duh SH, Wu AH et al (2010) Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 43(7–8):683–690
27. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian AS, Muntendam P, van Veldhuisen DJ, de Boer RA (2013) Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6:219–226
28. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 95:948–954
29. Moya-Mur JL, Garcia-Martin A, Garcia-LIedo A, Ruiz-Leria S, Jimenez-Nacher JJ, Megias-Sanz A, Taboada D, Muriel A (2010) Indexed left atrial volume is a more sensitive indicator of filling pressures and left heart function than is anteroposterior left atrial diameter. Echocardiography 27(9):1049–1055
30. Patel DA, Lavie CJ, Milani RV, Ventura HO (2011) Left atrial volume index predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction. Mayo Clin Proc 86(8):730–737
31. Shizuku J, Yamashita T, Ohba T, Kabaya T, Nitta K (2012) Left atrial volume is an independent predictor of all-cause mortality in chronic hemodialysis patients. Intern Med 51(12):1479–1485
32. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, Park SW, Bailey KR, Pellika PA (2003) Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 107:2207–2212
33. Barnes ME, Miyasaka Y, Seward JB et al (2004) Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc 79:1008–1014
34. Okada K, Mikami T, Kaga S, Onozuka H, Inoue M, Yokoyama S, Nishino H, Nishida M, Matsuno K, Iwano H, Yamada S, Tsutsui H (2011) Early diastolic mitral annular velocity at the interventricular septal annulus correctly reflects left ventricular longitudinal myocardial relaxation. Eur J Echocardiogr 12(12):917–923